By Andrew Pollack Hikma Pharmaceuticals agreed to pay about $2.65 billion in cash and shares for Boehringer Ingelheim’s generic drugs business in the United States. Boehringer Ingelheim said ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

The Catalysis group at Boehringer Ingelheim works with various internal and external partners to develop synthetic technologies that speed up the delivery of lifesaving drugs to patients. The webinar ...

San Antonio attorney Mikal Watts is among a group of lawyers that negotiated a settlement of as much as $2.2 billion to resolve claims by about 80,000 people who allege a discontinued version of the ...

As Hurricane Milton made landfall in Florida Wednesday night, drugmakers, regulators, hospitals and health agencies alike ...

CHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration ...

An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...

AstraZeneca is capping out-of-pocket costs for inhalers and related medication at no more than $35 per month, the drugmaker ...

Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome ...